| Title: | Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank |
| Journal: | Atherosclerosis |
| Published: | 27 Dec 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38219651/ |
| DOI: | https://doi.org/10.1016/j.atherosclerosis.2023.117437 |
| URL: | http://www.atherosclerosis-journal.com/article/S0021915023053583/pdf |
Publication 9068
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND AND AIMS: Elevated lipoprotein(a) [Lp(a)] is a genetic driver for atherosclerotic cardiovascular disease (ASCVD). We aimed to provide novel insights into the associated risk of elevated versus normal Lp(a) levels on major adverse cardiovascular events (MACE) in an incident ASCVD cohort.</p>
METHODS: This was an observational cohort study of incident ASCVD patients. MACE counts and incidence rates (IRs) per 100-person-years were reported for patients with normal (<65 nmol/L) and elevated (>150 nmol/L) Lp(a) within the first year after incident ASCVD diagnosis and overall follow-up. Cox proportional hazard models quantified the risk of MACE associated with a 100 nmol/L increase in Lp(a).</p>
RESULTS: The study cohort included 32,537 incident ASCVD patients; 5204 with elevated and 22,257 with normal Lp(a). Of those with elevated Lp(a), 41.2% had a subsequent MACE, versus 35.61% with normal Lp(a). Within the first year of follow-up, the IRs of composite MACE and coronary revascularisation were significantly higher (p < 0.001) in patients with elevated versus normal Lp(a) (IR difference 6.79 and 4.66). This trend was also observed in the overall follow-up (median 4.7 years). Using time to first subsequent MACE, a 100 nmol/L increase in Lp(a) was associated with an 8.0% increased risk of composite MACE, and 18.6% increased risk of coronary revascularisation during the overall follow-up period.</p>
CONCLUSIONS: The association of elevated Lp(a) with increased risk of subsequent MACE and coronary revascularisation highlights a population who may benefit from earlier and more targeted intervention for cardiovascular risk including Lp(a), particularly within the first year after ASCVD diagnosis. Proactive Lp(a) testing as part of routine clinical practice can help identify and better manage these higher-risk individuals.</p>
12 Authors
- Paul Welsh
- Anas Al Zabiby
- Hannah Byrne
- Harriet R Benbow
- Taha Itani
- Gabriella Farries
- Madlaina Costa-Scharplatz
- Philippe Ferber
- Lorraine Martin
- Rosemary Brown
- Ana Filipa Fonseca
- Naveed Sattar
1 Application
| Application ID | Title |
|---|---|
| 59456 | Using UK Biobank data to support the Novartis drug discovery and development pipeline |
Enabling scientific discoveries that improve human health